Go Pro
→ Trump goes 'all-in' on Grand Canyon energy breakthrough (From Behind the Markets) (Ad)tc pixel
NASDAQ:PPCB

Propanc Biopharma Q3 2025 Earnings Report

Propanc Biopharma logo
$0.60 -0.03 (-4.17%)
Closing price 04:00 PM Eastern
Extended Trading
$0.58 -0.02 (-3.46%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Propanc Biopharma EPS Results

Actual EPS
-$312.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Propanc Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Propanc Biopharma Announcement Details

Quarter
Q3 2025
Date
5/15/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Propanc Biopharma Earnings Headlines

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
September 22 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366329/0/en/propanc-biopharma-highlights-differentiated-prp-pancreatic-cancer-data-versus-emerging-pan-ras-program-eras-0015.html
Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363152/0/en/propanc-biopharma-positions-prp-s-emt-reversal-mechanism-as-a-complementary-backbone-to-emerging-ras-inhibitors-from-revolution-medicines-inc-and-erasca-inc.html
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before September 30, pointing to a critical shift ahead for tech and AI-related stocks.tc pixel
September 24 at 1:00 AM  |  TradeSmith (Ad)
PPCB Advances PRP Toward Phase 1b Study; Trial Start Planned For February 2027
September 9, 2026  |  rttnews.comhttps://www.rttnews.com/3689648/ppcb-advances-prp-toward-phase-1b-study-trial-start-planned-for-february-2027.aspx
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3358655/0/en/propanc-biopharma-to-initiate-world-first-phase-1b-first-in-human-study-of-prp-in-february-2027.html
Propanc Biopharma Reports PRP Preclinical Pancreatic Cancer Data Showing Over 90% Tumor Growth Inhibition
August 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/propanc-biopharma-reports-prp-preclinical-142914248.html
See More Propanc Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Propanc Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Propanc Biopharma and other key companies, straight to your email.

About Propanc Biopharma

Propanc Biopharma (NASDAQ:PPCB), Inc. is a biotechnology company focused on developing novel treatments for solid tumors. The company’s research centers on the use of proenzymes—precursors to digestive enzymes—as a potential therapeutic approach for targeting cancer cells and limiting tumor growth, recurrence and metastasis.

Propanc’s lead product candidate is PRP, an investigational proenzyme therapy being developed primarily for cancers with a high risk of recurrence, including pancreatic, ovarian and colorectal cancers. The company has described PRP as a formulation intended to act on cancer stem cells and other tumor-related mechanisms; its development remains subject to clinical and regulatory evaluation.

Propanc Biopharma was founded in Australia and has operated as a development-stage biotechnology company serving the global oncology market. The company is led by James Nathanielsz, who has served as chief executive officer and has been involved in advancing its proenzyme-based cancer program. Propanc’s activities have primarily consisted of research, preclinical development and clinical planning rather than commercialized pharmaceutical sales.

View Propanc Biopharma Profile
Earnings Tools